Literature DB >> 7862876

Neuroendocrine effects of sumatriptan.

J R Herdman1, N J Delva, R E Hockney, G M Campling, P J Cowen.   

Abstract

The neuroendocrine effects of the 5-HT receptor agonist, sumatriptan (6 mg subcutaneously), were studied in 11 healthy male subjects using a placebo-controlled, cross-over design. Compared to placebo, sumatriptan significantly lowered levels of plasma prolactin but increased those of plasma growth hormone. There was no effect on plasma cortisol concentrations. The neuroendocrine effects of sumatriptan differ from those of previously described 5-HT-receptor agonists, and may be a consequence of selective activation of 5-HT1D or 5-HT1B receptors. However, the present data cannot exclude the possibility that the neuroendocrine changes reflect nonspecific stress responses or changes in pituitary blood flow.

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 7862876     DOI： 10.1007/bf02245240

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN： 0033-3158            Impact factor:   4.530


  18 in total

1.  In vivo effects of sumatriptan (GR 43175) on extracellular levels of 5-HT in the guinea pig.

Authors:  A J Sleight; A Cervenka; S J Peroutka
Journal:  Neuropharmacology       Date:  1990-06       Impact factor: 5.250

2.  The pharmacological properties of the presynaptic serotonin autoreceptor in the pig brain cortex conform to the 5-HT1D receptor subtype.

Authors:  E Schlicker; K Fink; M Göthert; D Hoyer; G Molderings; I Roschke; P Schoeffter
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1989-07       Impact factor: 3.000

3.  Sumatriptan (GR 43175) interacts selectively with 5-HT1B and 5-HT1D binding sites.

Authors:  S J Peroutka; B G McCarthy
Journal:  Eur J Pharmacol       Date:  1989-04-12       Impact factor: 4.432

4.  The kinetics of 14C-GR43175 in rat and dog.

Authors:  F A Dallas; C M Dixon; R J McCulloch; D A Saynor
Journal:  Cephalalgia       Date:  1989       Impact factor: 6.292

5.  Selective 5-HT1A and 5-HT2 receptor-mediated adrenocorticotropin release in the rat: effect of repeated antidepressant treatments.

Authors:  S E Gartside; P M Ellis; T Sharp; P J Cowen
Journal:  Eur J Pharmacol       Date:  1992-10-06       Impact factor: 4.432

6.  A pharmacological analysis of the 5-HT receptor mediating inhibition of 5-HT release in the guinea-pig frontal cortex.

Authors:  D N Middlemiss; M E Bremer; S M Smith
Journal:  Eur J Pharmacol       Date:  1988-11-15       Impact factor: 4.432

Review 7.  Sumatriptan. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the acute treatment of migraine and cluster headache.

Authors:  K L Dechant; S P Clissold
Journal:  Drugs       Date:  1992-05       Impact factor: 9.546

Review 8.  Neuroendocrine tests of monoamine function in man: a review of basic theory and its application to the study of depressive illness.

Authors:  S A Checkley
Journal:  Psychol Med       Date:  1980-02       Impact factor: 7.723

9.  The distribution of 5-HT1D and 5-HT1E binding sites in human brain.

Authors:  S Lowther; F De Paermentier; M R Crompton; R W Horton
Journal:  Eur J Pharmacol       Date:  1992-11-03       Impact factor: 4.432

10.  Activation of the 5-HT1A receptor subtype increases rat plasma ACTH concentration.

Authors:  F Gilbert; C Brazell; M D Tricklebank; S M Stahl
Journal:  Eur J Pharmacol       Date:  1988-03-15       Impact factor: 4.432
View more
  4 in total

1.  Influence of age on the GH response to sumatriptan administration in man.

Authors:  V Coiro; R Volpi; C Davoli; G Caffarri; P Chiodera
Journal:  J Neural Transm Gen Sect       Date:  1995

Review 2.  Similarities and differences between pathological gambling and substance use disorders: a focus on impulsivity and compulsivity.

Authors:  Robert F Leeman; Marc N Potenza
Journal:  Psychopharmacology (Berl)       Date:  2011-11-05       Impact factor: 4.530

3.  Neuroendocrine effects of subcutaneous sumatriptan in patients with migraine.

Authors:  I Rainero; W Valfrè; L Savi; S Gentile; L Pinessi; L Gianotti; E Arvat; E Ghigo; P Del Rizzo; P Calvelli; P Limone
Journal:  J Endocrinol Invest       Date:  2001-05       Impact factor: 4.256

4.  Paroxetine treatment and the prolactin response to sumatriptan.

Authors:  Y K Wing; E M Clifford; B D Sheehan; G M Campling; R A Hockney; P J Cowen
Journal:  Psychopharmacology (Berl)       Date:  1996-04       Impact factor: 4.530
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.